Does the Use of Intrathecal Morphine Increase the Length of Hospital Stay in Fast Track Orthopedic Procedures?

• Status: Recruiting
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a clinical trial of intrathecal morphine for patients Patient with primary as well as revision knee and hip arthroplasty under regional anesthesia. This study would include a total of 134 patients. It is the intention to randomize these patients postoperatively into 2 groups of patients:

Group 1 - Patients will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and 15 mcg of fentanyl for spinal anesthesia.

Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.

It is postulated that the use of intrathecal morphine may be associated with an increase length of stay in the hospital.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
• Treatments: Morphine

Criteria

Inclusion Criteria:

• ASA 1-3

• Age 18 to 85 years

• BMI 18 to 40 kg/cm2

• Patient with primary as well as revision knee and hip arthroplasty under regional anesthesia only.

• Provision of written informed consent.

Exclusion Criteria:

• Language barrier or difficulty in communication: inability to read write or speak English

• Allergy to morphine

• Patients under increased risk for respiratory depression with intrathecal morphine (central apnea)

• Patients with pre-existing urinary problems

• Women of child bearing potential not on birth control

• Patients with chronic pain who are currently on pain medications

• Patients with cognitive impairment

• Patients who have alcohol and/or other substance dependency